RxDoctor Payments Data

Tamara Sealy, MD

Family Medicine · Zephyrhills, FLNPI 1225477094

Payments from drug & device makers

$3,637in general payments, 2019–2025

Across 209 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$868
  • Lilly USA, LLC$463
  • AstraZeneca$368
  • GSK$283
  • Astellas Pharma US Inc$253
  • Boehringer Ingelheim$219
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,53797%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,637 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$83,190
Medicare patients
170
Services billed
1,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$65,469
MounjaroTirzepatide32$54,702
JardianceEmpagliflozin54$46,210
FarxigaDapagliflozin Propanediol27$31,782
RybelsusSemaglutide13$27,071
Repatha SureclickEvolocumab21$22,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,788
MyrbetriqMirabegron11$15,572
Praluent PenAlirocumab22$12,184
Breo ElliptaFluticasone/Vilanterol22$9,629
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,749
Albuterol Sulfate HfaAlbuterol Sulfate86$2,673
Atorvastatin Calcium274$2,452
Rosuvastatin Calcium157$1,814
Gabapentin132$1,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$868$92,54065 claims
Lilly USA, LLCMounjaro$463$54,70232 claims
Boehringer IngelheimJardiance$219$46,21054 claims
AstraZenecaFarxiga$368$31,78227 claims
GSKTrelegy Ellipta, Breo Ellipta$283$29,41738 claims
Astellas Pharma US IncMyrbetriq$253$15,57211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →